Sanam Loghavi1, Joseph D Khoury2. 1. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 0072, Houston, TX, 77030, USA. sloghavi@mdanderson.org. 2. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 0072, Houston, TX, 77030, USA. jkhoury@mdanderson.org.
Abstract
PURPOSE OF REVIEW: The goal of this review is to provide a practical and comprehensive update on changes in the classification of chronic myelomonocytic leukemia (CMML) and a summary of the most recent developments in our understanding of its genomic landscape, prognostic models, and therapeutic approaches. RECENT FINDINGS: The 2017 revision of the World Health Organization (WHO) classification includes substantial changes to the subclassification CMML. The clinical utility of the newly revised subclassification scheme is discussed. In addition, we provide an overview of the genetic changes involved in the pathogenesis of CMML and discuss the clinical utility of the more recently developed molecularly integrated prognostic models and their management and therapeutic implications. Finally, we provide an overview of the currently available treatment options for patients with CMML. The classification of CMML as well as our understanding of its genomic landscape and optimal treatment approaches has advanced significantly over the past decade but remains in flux.
PURPOSE OF REVIEW: The goal of this review is to provide a practical and comprehensive update on changes in the classification of chronic myelomonocytic leukemia (CMML) and a summary of the most recent developments in our understanding of its genomic landscape, prognostic models, and therapeutic approaches. RECENT FINDINGS: The 2017 revision of the World Health Organization (WHO) classification includes substantial changes to the subclassification CMML. The clinical utility of the newly revised subclassification scheme is discussed. In addition, we provide an overview of the genetic changes involved in the pathogenesis of CMML and discuss the clinical utility of the more recently developed molecularly integrated prognostic models and their management and therapeutic implications. Finally, we provide an overview of the currently available treatment options for patients with CMML. The classification of CMML as well as our understanding of its genomic landscape and optimal treatment approaches has advanced significantly over the past decade but remains in flux.
Authors: Mrinal M Patnaik; Daniela Barraco; Terra L Lasho; Christy M Finke; Curtis A Hanson; Rhett P Ketterling; Naseema Gangat; Ayalew Tefferi Journal: Am J Hematol Date: 2016-12-07 Impact factor: 10.047
Authors: Mrinal M Patnaik; Terra L Lasho; Katherine P Hoversten; Christy M Finke; Rhett P Ketterling; Curtis A Hanson; Naseema Gangat; Ayalew Tefferi; Animesh Pardanani Journal: Leukemia Date: 2018-04-02 Impact factor: 11.528
Authors: M M Patnaik; E Padron; R R LaBorde; T L Lasho; C M Finke; C A Hanson; J M Hodnefield; R A Knudson; R P Ketterling; A Al-kali; A Pardanani; N A Ali; R S Komrokji; R S Komroji; A Tefferi Journal: Leukemia Date: 2013-03-27 Impact factor: 11.528
Authors: P Solal-Celigny; B Desaint; A Herrera; C Chastang; M Amar; M Vroclans; N Brousse; F Mancilla; M Renoux; J F Bernard Journal: Blood Date: 1984-03 Impact factor: 22.113
Authors: Sanam Loghavi; Jonathan L Curry; Guillermo Garcia-Manero; Keyur P Patel; Jie Xu; Joseph D Khoury; Carlos A Torres-Cabala; Priyadharsini Nagarajan; Phyu P Aung; Bernard R Gibson; Brandon P Goodwin; Brent C Kelly; Brinda R Korivi; L Jeffrey Medeiros; Victor G Prieto; Hagop M Kantarjian; Carlos E Bueso-Ramos; Michael T Tetzlaff Journal: J Cutan Pathol Date: 2017-09-27 Impact factor: 1.587
Authors: Yanbo Nie; Liang Shao; Hong Zhang; Colin K He; Hongyu Li; Junyan Zou; Long Chen; Huaiyue Ji; Hao Tan; Yani Lin; Kun Ru Journal: Exp Hematol Oncol Date: 2022-05-24